Revvity Inc. (NYSE:RVTY) Stock Has Consensus Target Price of $116.57 According to Analysts

Key Points

• Analyst sentiment is neutral: Eighteen brokerages give Revvity an average “Hold” rating, with a consensus 12-month price target of $116.57.
• Revvity exceeded quarterly expectations, reporting $1.41 in EPS versus the $1.21 consensus and $729.69 million in revenue versus $702.96 million expected, while revenue declined 1.3% year over year.
• Shares opened at $149.18, near the 12-month high of $158.28, and the company declared a quarterly dividend of $0.07 per share; insiders sold 9,046 shares worth approximately $1.28 million during the latest quarter.

Revvity Inc. (NYSE:RVTY - Get Free Report) has received an average rating of "Hold" from the eighteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Fourteen research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $116.57.

Several equities analysts have recently commented on the stock. Evercore reaffirmed an "outperform" rating on shares of Revvity in a research report on Wednesday, August 5th. KeyCorp upped their price objective on Revvity from $125.00 to $165.00 and gave the company an "overweight" rating in a research note on Friday, September 4th. Sanford C. Bernstein initiated coverage on Revvity in a research note on Friday, June 26th. They set a "market perform" rating and a $115.00 price objective on the stock. Zacks Research raised Revvity from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 4th. Finally, Weiss Ratings upgraded Revvity from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, July 30th.

Insider Buying and Selling at Revvity

In other Revvity news, insider Tajinder Vohra sold 7,330 shares of the business's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the sale, the insider owned 6,635 shares in the company, valued at $934,738.80. The trade was a 52.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Maxwell Krakowiak sold 1,631 shares of the stock in a transaction on Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the sale, the insider directly owned 14,781 shares in the company, valued at $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 9,046 shares of company stock valued at $1,277,685. 0.85% of the stock is owned by insiders.

Hedge Funds Weigh In On Revvity

A number of large investors have recently bought and sold shares of RVTY. New Mexico Educational Retirement Board raised its stake in Revvity by 1.9% during the 4th quarter. New Mexico Educational Retirement Board now owns 5,416 shares of the company's stock worth $524,000 after buying an additional 100 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in Revvity by 5.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,074 shares of the company's stock worth $231,000 after buying an additional 106 shares during the period. EverSource Wealth Advisors LLC lifted its stake in Revvity by 17.0% in the first quarter. EverSource Wealth Advisors LLC now owns 749 shares of the company's stock valued at $66,000 after buying an additional 109 shares in the last quarter. Angeles Wealth Management LLC boosted its holdings in shares of Revvity by 2.0% in the second quarter. Angeles Wealth Management LLC now owns 5,804 shares of the company's stock valued at $646,000 after buying an additional 112 shares during the period. Finally, Tema ETFs LLC boosted its holdings in shares of Revvity by 8.1% in the second quarter. Tema ETFs LLC now owns 1,946 shares of the company's stock valued at $217,000 after buying an additional 145 shares during the period. Institutional investors own 86.65% of the company's stock.

Revvity Stock Down 2.4%

Shares of NYSE:RVTY opened at $149.18 on Friday. The firm has a market cap of $16.65 billion, a PE ratio of 71.04, a price-to-earnings-growth ratio of 2.78 and a beta of 1.06. The company has a fifty day simple moving average of $127.45 and a 200 day simple moving average of $108.40. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36. Revvity has a 12-month low of $81.22 and a 12-month high of $158.28.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, beating analysts' consensus estimates of $1.21 by $0.20. The firm had revenue of $729.69 million for the quarter, compared to the consensus estimate of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The firm's revenue was down 1.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.18 EPS. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts anticipate that Revvity will post 5.36 EPS for the current fiscal year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity's payout ratio is currently 13.33%.

Revvity Company Profile

Revvity, Inc NYSE: RVTY is a life sciences and diagnostics company that provides technologies, products and services used in biological research, drug discovery, clinical testing and healthcare. The company serves pharmaceutical and biotechnology companies, academic and government research institutions, hospitals, clinical laboratories and other healthcare organizations.

Its portfolio includes instruments, reagents, consumables, software and related services for areas such as genomics, proteomics, cellular analysis, imaging and multiplex testing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.